Clinical trial
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
NCT05086692 is registered in ClinicalTrials.gov with Medicenna Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
- Lead sponsor
- Medicenna Therapeutics, Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- August 27, 2021
- Completion date
- December 30, 2028
- Enrollment
- 160 (estimated)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.
acral melanoma, advanced solid tumor, basal cell carcinoma, bladder cancer, cancer with a high tumor mutational burden, cervical cancer, cervical cancers, clear cell renal cell carcinoma, colorectal cancer (msi-h), cutaneous melanoma, cutaneous squamous cell carcinoma, dmmr cancer, dmmr solid malignant tumor, endometrial cancer, endometrial carcinoma, epithelial ovarian carcinoma, esophageal cancer, fallopian tube cancer, gastric cancer, gastroesophageal junction (gej) cancer, merkel cell carcinoma, msi-h cancer, msi-h solid malignant tumor, mucosal melanoma, non-small cell lung cancer non-squamous, non-small cell lung cancer squamous, ovarian cancer, pancreas adenocarcinoma (msi-h), pleural mesothelioma, primary peritoneal cancer, skin cancer, solid tumor, solid tumor, adult, squamous cell carcinoma of head and neck, triple negative breast cancer, unresectable solid tumor, viral cancer